Science & Technology
IND-enabling studies of KTX-1161, a novel NRF2 activator for corneal endothelial disease
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44EY038121-01
Award Ceiling
$400K
Award Floor
$400K
Close Date
Aug 31, 2026
169 days leftTotal Funding
$400K
Expected Awards
1
Posted Date
Sep 30, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R44EY038121-01
Description
SBIR Phase Phase I award: "IND-enabling studies of KTX-1161, a novel NRF2 activator for corneal endothelial disease" awarded to KURIA THERAPEUTICS, INC in LITTLE ROCK, Arkansas. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $399,865. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.